文献速递乳腺癌

HER2阴性转移性乳腺癌患者贝伐珠单抗的真实世界与试验成本-效果分析:东南荷兰乳腺癌联盟研究

Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
PubMed 文献 · Eur J Cancer · 2017-02-27

该研究构建状态转移模型,基于真实世界队列与E2100试验两种情景,比较贝伐珠单抗联合紫杉类与紫杉类单药治疗HER2阴性转移性乳腺癌的成本-效果。真实世界情景增量成本€56,213、增量QALY 0.362、ICER €155,261/QALY;试验情景增量成本€52,750、增量QALY 0.189、ICER €278,711/QALY。按荷兰非正式阈值,两种情景下贝伐珠单抗联合紫杉类均不被认为具有成本-效果。

要点

  • 真实世界情景下贝伐珠单抗联合紫杉类的ICER为€155,261/QALY。
  • 试验情景下贝伐珠单抗联合紫杉类的ICER为€278,711/QALY。
  • 按荷兰非正式阈值,两种情景均不认为贝伐珠单抗联合紫杉类具有成本-效果。

核心结论

  • 根据荷兰非正式阈值,贝伐珠单抗联合紫杉类治疗HER2阴性转移性乳腺癌在真实世界和试验情景下均不被认为具有成本-效果。

研究设计与样本

  • 构建状态转移模型估算两种治疗的成本、生命年(LYs)和质量调整生命年(QALYs)。
  • 设置真实世界情景和试验情景,转移概率分别主要基于真实世界队列研究和E2100试验。
  • 两种情景下成本和效用参数估计均取自真实世界队列研究,采用荷兰医疗保健视角。

主要发现

  • 真实世界情景下,贝伐珠单抗联合紫杉类较紫杉类单药增量成本为€56,213,增量QALY为0.362,ICER为€155,261/QALY。
  • 试验情景下,贝伐珠单抗联合紫杉类较紫杉类单药增量成本为€52,750,增量QALY为0.189,ICER为€278,711/QALY。

关键数值与推荐

  • 真实世界情景:贝伐珠单抗联合紫杉类较紫杉类单药增量成本€56,213,增量QALY 0.362,ICER €155,261/QALY。
  • 试验情景:贝伐珠单抗联合紫杉类较紫杉类单药增量成本€52,750,增量QALY 0.189,ICER €278,711/QALY。
  • 荷兰非正式阈值下,两种情景下贝伐珠单抗联合紫杉类均不被认为具有成本-效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of our analysis was to assess the real-world cost-effectiveness of bevacizumab in addition to taxane treatment versus taxane monotherapy for HER2-negative metastatic breast cancer compared with the cost-effectiveness based on the efficacy results from a trial. METHODS: A state transition model was built to estimate costs, life years (LYs) and quality-adjusted life years (QALYs) for both treatments. Two scenarios were examined: a real-world scenario and a trial-based scenario in which transition probabilities were primarily based on a real-world cohort study and the E2100 trial, respectively. In both scenarios, costs and utility parameter estimates were extracted from the real-world cohort study. Moreover, the Dutch health care perspective was adopted. RESULTS: In both the real-world and trial scenarios, bevacizumab-taxane is more expensive (incremental costs of €56,213 and €52,750, respectively) and more effective (incremental QALYs of 0.362 and 0.189, respectively) than taxane monotherapy. In the real-world scenario, bevacizumab-taxane compared to taxane monotherapy led to an incremental cost-effectiveness ratio (ICER) of €155,261 per QALY gained. In the trial scenario, the ICER amounted to €278,711 per QALY gained. CONCLUSION: According to the Dutch informal threshold, bevacizumab in addition to taxane treatment was not considered cost-effective for HER2-negative metastatic breast cancer both in a real-world and in a trial scenario.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. van Kampen RJW, Ramaekers BLT, Lobbezoo DJA, et al. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. Eur J Cancer. 2017. PMID: 28245951. doi:10.1016/j.ejca.2017.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。